AT399277B - Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung - Google Patents

Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung Download PDF

Info

Publication number: AT399277B
Authority: AT; Austria
Prior art keywords: weight; parts; mannitol; piroxicam; capsules
Prior art date: 1988-10-28

Application number

AT0247489A

Other languages

German (de)

English (en)

Other versions

ATA247489A (de

Inventor

Pal Dr Chem Ing Fekete

Denes Bezzegh

Istvan Dr Simonyi

Biborka Dr Maroshelyi

Katalin Zukovics

Janos Tombor

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-28

Filing date

1989-10-27

Publication date

1995-04-25

1989-10-27 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

1994-09-15 Publication of ATA247489A publication Critical patent/ATA247489A/de

1995-04-25 Application granted granted Critical

1995-04-25 Publication of AT399277B publication Critical patent/AT399277B/de

Links

QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims description 29
229960002702 piroxicam Drugs 0.000 title claims description 20
238000002360 preparation method Methods 0.000 title claims description 19
238000000034 method Methods 0.000 title claims description 11
239000007787 solid Substances 0.000 title claims description 7
238000004519 manufacturing process Methods 0.000 title description 9
239000002775 capsule Substances 0.000 claims description 34
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
239000004480 active ingredient Substances 0.000 claims description 24
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 21
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
239000008101 lactose Substances 0.000 claims description 17
235000019359 magnesium stearate Nutrition 0.000 claims description 14
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
229930195725 Mannitol Natural products 0.000 claims description 13
239000000594 mannitol Substances 0.000 claims description 13
235000010355 mannitol Nutrition 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 13
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
229920002261 Corn starch Polymers 0.000 claims description 11
239000008120 corn starch Substances 0.000 claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
239000000377 silicon dioxide Substances 0.000 claims description 6
235000012239 silicon dioxide Nutrition 0.000 claims description 6
229910002016 Aerosil® 200 Inorganic materials 0.000 claims description 4
239000007884 disintegrant Substances 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
239000000084 colloidal system Substances 0.000 claims description 2
229910052814 silicon oxide Inorganic materials 0.000 claims 1
238000005303 weighing Methods 0.000 claims 1
239000013543 active substance Substances 0.000 description 7
239000000843 powder Substances 0.000 description 6
239000006185 dispersion Substances 0.000 description 5
FVTSYHPRVGNAQI-UHFFFAOYSA-N 2-aminoethanol;4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NCCO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 FVTSYHPRVGNAQI-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000000265 homogenisation Methods 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
239000011148 porous material Substances 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
238000009826 distribution Methods 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229920003133 pregelled starch Polymers 0.000 description 2
238000003825 pressing Methods 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
IVTQBYAUJMDQFZ-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,2-benzothiazine-3-carboxamide Chemical compound C1=CC=C2C(O)=C(C(N)=O)N(C)SC2=C1 IVTQBYAUJMDQFZ-UHFFFAOYSA-N 0.000 description 1
229910000906 Bronze Inorganic materials 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
229940124346 antiarthritic agent Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000010974 bronze Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
-1 polyvinylpyrroidone Chemical compound 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005029 sieve analysis Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000001665 trituration Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT0247489A 1988-10-28 1989-10-27 Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung AT399277B (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU885621A HU200926B (en)	1988-10-28	1988-10-28	Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules

Publications (2)

Publication Number	Publication Date
ATA247489A ATA247489A (de)	1994-09-15
AT399277B true AT399277B (de)	1995-04-25

Family

ID=10970484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT0247489A AT399277B (de)	1988-10-28	1989-10-27	Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung

Country Status (9)

Country	Link
JP (1)	JPH02172918A (he)
AT (1)	AT399277B (he)
CA (1)	CA2001673C (he)
DE (1)	DE3936112C2 (he)
FR (1)	FR2638357B1 (he)
GB (1)	GB2224207B (he)
HU (1)	HU200926B (he)
IL (1)	IL92138A (he)
IT (1)	IT1239542B (he)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
JP2964195B2 (ja) *	1992-04-28	1999-10-18	エスエス製薬株式会社	ピロキシカム錠及びその製造法
DE19603402A1 (de) *	1995-02-24	1996-08-29	Basf Ag	Weichgelatinekapseln
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
JP3797387B2 (ja) *	1996-06-14	2006-07-19	協和醗酵工業株式会社	口腔内速崩壊錠
AU763143B2 (en) *	1998-04-08	2003-07-17	Kyowa Hakko Kirin Co., Ltd.	Tablet manufacturing method and tablet
JP2000095674A (ja)	1998-09-22	2000-04-04	Sato Pharmaceutical Co Ltd	口腔内崩壊時間短縮化錠剤の製造方法及び装置
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
JP4633469B2 (ja) *	2002-12-16	2011-02-16	キッセイ薬品工業株式会社	経口固形医薬
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
NZ589750A (en)	2004-10-21	2012-07-27	Aptalis Pharmatech Inc	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
PT1920786E (pt)	2005-07-25	2011-12-28	Otsuka Pharma Co Ltd	Preparação oral para avaliar a capacidade metabólica da pirimidina
CN102958515A (zh)	2009-12-02	2013-03-06	阿普塔利斯制药有限公司	非索非那定微胶囊及含有非索非那定微胶囊的组合物
CA2882528A1 (en)	2012-08-20	2014-02-27	Otsuka Pharmaceutical Co., Ltd.	Method for measuring carbohydrate metabolism ability, and composition for use in said method
KR20210014204A (ko)	2013-03-15	2021-02-08	오츠카 세이야쿠 가부시키가이샤	지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4350689A (en) *	1980-02-15	1982-09-21	American Cyanamid Company	Combinations of agents which give enhanced anti-inflammatory activity
EP0066459A1 (en) *	1981-06-01	1982-12-08	Pfizer Inc.	Crystalline benzothiazine dioxide salts
EP0196434A1 (fr) *	1985-03-20	1986-10-08	Societe Des Produits Nestle S.A.	Procédé pour la préparation d'une composition à base d'un principe actif de faible hydrosolubilité finement divisé

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3591584A (en) *	1968-08-27	1971-07-06	Pfizer	Benzothiazine dioxides
GB1308533A (en) *	1969-06-02	1973-02-21	Pfizer	Benzothiazine dioxides as anti-thombotic agents
JPS55129221A (en) *	1979-03-29	1980-10-06	Kaken Pharmaceut Co Ltd	Preparation of oral preparation containing hardly soluble medicine
RO88420A (ro) *	1983-04-25	1986-01-30	Pfizer Inc,Us	Procedeu pentru prepararea unor saruri bazice de piroxican depuse pe suporturi farmaceutice
DE3419128A1 (de) *	1984-05-23	1985-11-28	Bayer Ag, 5090 Leverkusen	Dihydropyridinpraeparate und verfahren zu ihrer herstellung
ES545221A0 (es) *	1985-07-02	1986-01-01	Ferrer Int	Procedimiento de obtencion de particulas de 4-hidroxi-2-me- til-n-2-piridil-2h-1,2-benzotiazina-3-carboxamida-1,1-dioxi-do(piroxicam) recubiertas

1988
- 1988-10-28 HU HU885621A patent/HU200926B/hu unknown
1989
- 1989-10-19 JP JP1270514A patent/JPH02172918A/ja active Pending
- 1989-10-27 CA CA002001673A patent/CA2001673C/en not_active Expired - Fee Related
- 1989-10-27 IT IT22164A patent/IT1239542B/it active IP Right Grant
- 1989-10-27 AT AT0247489A patent/AT399277B/de not_active IP Right Cessation
- 1989-10-27 IL IL9213889A patent/IL92138A/he not_active IP Right Cessation
- 1989-10-27 GB GB8924286A patent/GB2224207B/en not_active Expired - Lifetime
- 1989-10-27 FR FR8914117A patent/FR2638357B1/fr not_active Expired - Fee Related
- 1989-10-30 DE DE3936112A patent/DE3936112C2/de not_active Expired - Fee Related

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4350689A (en) *	1980-02-15	1982-09-21	American Cyanamid Company	Combinations of agents which give enhanced anti-inflammatory activity
EP0066459A1 (en) *	1981-06-01	1982-12-08	Pfizer Inc.	Crystalline benzothiazine dioxide salts
EP0196434A1 (fr) *	1985-03-20	1986-10-08	Societe Des Produits Nestle S.A.	Procédé pour la préparation d'une composition à base d'un principe actif de faible hydrosolubilité finement divisé

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. SCHORMÜLLER, HANDBUCH DER LEBENSMITTELCHEMIE, BAND III/1. TEIL, SPRINGER-VERLAG, BERLIN HEIDELBERG, NEW YORK, 1968, SEITEN 389-397 *

Also Published As

Publication number	Publication date
IT8922164A1 (it)	1991-04-27
CA2001673A1 (en)	1990-04-28
GB2224207B (en)	1992-06-10
GB2224207A (en)	1990-05-02
GB8924286D0 (en)	1989-12-13
FR2638357B1 (fr)	1993-10-22
IT1239542B (it)	1993-11-05
DE3936112C2 (de)	1999-02-18
HU200926B (en)	1990-09-28
IT8922164A0 (it)	1989-10-27
HUT51143A (en)	1990-04-28
JPH02172918A (ja)	1990-07-04
FR2638357A1 (fr)	1990-05-04
CA2001673C (en)	1996-08-27
DE3936112A1 (de)	1990-05-31
ATA247489A (de)	1994-09-15
IL92138A (he)	1994-08-26
IL92138A0 (en)	1990-07-12

Legal Events

Date	Code	Title	Description
1999-05-15	ELJ	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
AT399277B (de)	1995-04-25	Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung
DE3877764T2 (de)	1993-05-13	Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren.
EP0272265B1 (de)	1991-05-22	Zerfallstablette und verfahren zu ihrer herstellung
DE60036205T2 (de)	2008-05-21	Granulat bestehend aus Stärke und Laktose
DE69400215T2 (de)	1996-10-31	Tramadol enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe
DE68903846T2 (de)	1993-06-09	Neue galenische form von fenofibrat.
DE69712332T2 (de)	2002-10-02	Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung
DE69531957T2 (de)	2004-08-12	Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
DE69629755T2 (de)	2004-07-01	Irbesartanhaltiges Arzneimittel
DE69520768T2 (de)	2001-08-23	Pharmazeutische Zubereitungen, die Fluoxetin enthalten
DE69022452T2 (de)	1996-03-14	Direktkomprimierte Cholestyramintablette und lösungsmittelfreier Überzug dafür.
DE69802832T2 (de)	2002-06-20	Gepresste nitroglycerintablette und verfahren zu ihrer herstellung
DE69233130T2 (de)	2005-06-02	Kaubare zusammensetzung zur arzneimittelfreisetzung
EP3174531B1 (de)	2019-11-27	Direkt verpressbare zusammensetzung enthaltend mikrokristalline cellulose
EP3174530B1 (de)	2018-08-29	Direkt verpressbare polyvinylalkohole
DE29825080U1 (de)	2004-11-04	Pharmazeutische Fenofibratzusammensetzung mit erhöhter Bioverfügbarkeit
CH639845A5 (en)	1983-12-15	Solid depot pharmaceutical preparations and process for their production
DE3220263A1 (de)	1982-12-16	Komprimierte kautablette und verfahren zu deren herstellung
EP1077703B1 (de)	2003-03-26	Orale arzneiformen mit reproduzierbarer wirkstofffreisetzung von gatifloxacin oder pharmazeutisch verwendbaren salzen oder hydraten
DE2611041A1 (de)	1976-10-14	Retard-formulierung
EP0250648B1 (de)	1991-08-21	Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen
DE2433285A1 (de)	1975-01-30	(verzoegerungs-)mikrokapseln enthaltende tabletten und verfahren zur herstellung derselben
DE69518237T2 (de)	2001-02-22	Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff
AT401871B (de)	1996-12-27	Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
DE69712100T2 (de)	2002-11-28	Valproinsäure enthaltende mikrosphären für orale verabreichung